GlassScriptPhysician profile
Richa Mishra
NPI 1346400207
$4,896.54
in general payments reported to CMS, 2019-2025
20 companies · $1,108 in 2025
The $1,108 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $226 · 2021: $151 · 2022: $772 · 2023: $1,248 · 2024: $1,150 · 2025: $1,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,252 · Education: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,251.86 |
| Education | $253.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,675.07 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $660.84 | 2019-2025 | |
| Janssen Biotech, INC. | $485.83 | 2019-2025 | Tremfya |
| Amgen INC. | $469.47 | 2019-2025 | Enbrel, Krystexxa, Otezla |
| Ucb, INC. | $324.41 | 2022-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $309.28 | 2020-2025 | Benlysta |
| Pfizer INC. | $227.26 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $199.35 | 2019-2023 | Orencia |
| Cumberland Pharmaceuticals, INC. | $183.35 | 2022 | |
| Ani Pharmaceuticals, INC. | $176.23 | 2022-2024 | Purified Cortrophin Gel |
| Kiniksa Pharmaceuticals International, Plc | $33.22 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $27.88 | 2023-2024 | Saphnelo |
| Genzyme Corporation | $20.18 | 2023 | |
| Scilex Pharmaceuticals INC. | $16.24 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $15.25 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $14.97 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.78 | 2022 | |
| Aurinia Pharma U.S., INC. | $14.66 | 2023 | Lupkynis |
| Horizon Therapeutics Plc | $14.50 | 2023 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $13.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richa Mishra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.